Patents by Inventor Mikkel Jessing

Mikkel Jessing has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10351561
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 16, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgard, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • Publication number: 20190194204
    Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: August 1, 2018
    Publication date: June 27, 2019
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
  • Publication number: 20190194189
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 27, 2019
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Jan Kehler, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson, Mauro Marigo
  • Publication number: 20190185489
    Abstract: The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: December 12, 2018
    Publication date: June 20, 2019
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Jan Kehler, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson, Mauro Marigo
  • Publication number: 20190105302
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: July 12, 2018
    Publication date: April 11, 2019
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgàrd, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 10238654
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 26, 2019
    Assignee: MINDIMMUNE THERAPEUTICS, INC.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Publication number: 20190062335
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 7, 2018
    Publication date: February 28, 2019
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • Patent number: 10150771
    Abstract: The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: December 11, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Mikkel Jessing
  • Patent number: 10124010
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 13, 2018
    Assignee: MindImmune Therapeutics, Inc.
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Patent number: 10034861
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: July 31, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 10011606
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: July 3, 2018
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing
  • Publication number: 20180177793
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Application
    Filed: March 19, 2018
    Publication date: June 28, 2018
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Publication number: 20180179200
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgard, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • Patent number: 9861639
    Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: January 9, 2018
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang
  • Publication number: 20180000786
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 4, 2018
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Publication number: 20170298072
    Abstract: The present invention provides triazolopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 19, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Mikkel Jessing
  • Publication number: 20170291901
    Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: April 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Karsten Juhl, Mikkel Jessing, Morten Langgård, Paulo Jorge Vieira Vital, Mauro Marigo, Jan Kehler, Lars Kyhn Rasmussen
  • Publication number: 20170291903
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 12, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl
  • Publication number: 20170202836
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of epilepsy.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper
  • Patent number: 9649308
    Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of pain.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: May 16, 2017
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Lars Kyhn Rasmussen, Mikkel Jessing, Eman Mohamed Eldemenky, Bin Chen, Yu Jiang, Allen T. Hopper